US Dementia Cases to Double by 2060: Daily Dose
Your daily dose of the clinical news you may have missed.
Hims & Hers Super Bowl Ad for Semaglutide "Nothing Short of Reckless," Says Partnership for Safe Medicines
In letters to the FDA and Fox Broadcasting, PSM enumerated the laws abrogated and the potential harms of the ad being viewed by 200 million people on February 9, 2025.
FDA Approves New Wearable Treatment for Parkinson Disease
Onapgo is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in people with advanced Parkinson disease.
Opioid Prescribing Has Come a Long Way, According to Stanford Pain Expert Edward Mariano, MD, MAS
Opioid prescribing has seen its extremes, from the 5th Vital Sign era in the aughts to the CDC restrictions of 2016. Mariano talks about the environment right now.
Diabetes Caution: FDA Warns of Risk of Missing Critical Alerts from Smartphone-Compatible Diabetes Devices
Hardware or software changes as well as user adjustments may disable or mute alerts for elevated glycemia, medication use, and other diabetes management essentials, the agency said.
New Study Links Major Depressive Disorder to Specific Changes in Eating Preferences
People with MDD demonstrated a preference for carbohydrate-rich foods and reduced reward from fat- and protein-rich foods, according to new research.
Viking Therapeutics Advances 3 Potential Obesity Treatments Based on Promising 2024 Clinical Trial Results
A GLP-1/GIP dual agonist in both subcutaneous and oral tablet formulations and a novel dual amylin and calcitonin receptor agonist lead the company's pipeline for antiobesity medications.
FDA Greenlights Symbravo for Acute Treatment of Migraine: Daily Dose
Premature Menopause May Increase Risk of Type 2 Diabetes Suggests Study of 1.1 Million Women
Premature menopause, authors said, should be included in diabetes management guidelines as a risk factor to support screening and prevention.
Investigators Identify Hemoglobin A1c/HDL-C as a Predictor of Stroke Risk in Older Adults
Elevated HbA1c/HDL-C ratios significantly increased stroke risk, even after adjusting for confounding factors, reported authors of a recent study.
Roche Receives FDA 510(k) Clearance for First US Blood Test Measuring Lp(a) in Molar Units
The Tina-quant® Lipoprotein (a) Gen.2 Molarity assay measures Lp(a) in molar units, providing a more accurate particle-based risk assessment than mass units.
Study Identifies Key Symptoms of Topical Steroid Withdrawal: Daily Dose
New ACP Guidelines on Prevention of Episodic Migraine Cite Lack of Comparative Evidence for Treatments
Pharmacologic treatment to prevent episodic migraine should follow a sequential trial approach that considers medication cost, headache triggers, adherence, and lifestyle interventions.
Delgocitinib Effective in Adolescents with CHE in Phase 3 DELTA TEEN Trial
With no FDA-approved treatments for moderate-to-severe chronic hand eczema in the teen population, the late-stage topline data are very promising.
MindMed Initiates Second Phase 3 Trial of Psychedelic MM120 for Generalized Anxiety Disorder
The first patient was dosed in the Panorama study assessing MM120 ODT, a form of LSD, for the treatment of GAD.
AI-Assisted Mammography Boosts Breast Cancer Detection by 29% in Large Study
Results from the MASAI clinical trial also showed that AI-assisted screening reduced screen-reading workload without increasing the rate of false-positives.
World Cancer Day 2025: 7 Screening Recommendations from the USPSTF
World Cancer Day 2025 urges focus on the unique personal journey underlying every cancer diagnosis; individual recommendations for regular screening is where that can start.
Inhaled Psychedelic GH001 Significantly and Rapidly Reduces Symptoms in Treatment Resistant Depression in Phase 2b Clinical Trial
GH001, an inhalable 5-MeO-DMT therapy, led to a -15.5 MADRS score reduction by day 8 in patients with treatment-resistant depression.
FDA Approves Monthly Lecanemab for Early-Stage Alzheimer Disease: Daily Dose
Symbravo Mechanism of Action and Patient Selection, with PI Stewart Tepper, MD
Tepper, principal investigator for phase 3 trials of Symbravo as acute treatment for migraine in adults, reviews the new drug's dual MOA and target patient populations.
